Join the club for FREE to access the whole archive and other member benefits.

Jimmy Yen-Chu Lin

Chief Executive Officer at Insilico Medicine Taiwan

Yen-Chu Lin obtained his PhD from ETH Zurich (Switzerland) working at Gisbert Schneider lab where he pioneered in the peptide research field adopting machine learning approaches combining with experimental-lead strategies or with pharmacology-driven concepts to multidimensionally design peptides with desired activities and selectivity.
His post-doc with Sir David Lane and Gregory Verdine focused on developing peptides and mini-proteins targeting critical protein-protein interaction in cancers by diversity-oriented biological techniques.
He has published several influential papers in high-impact journals in computational chemistry and chemical biology field. In 2018 he joined Insilico Taiwan, as CSO leading the research efforts in the company.
He now assumes the role of CEO of Insilico Taiwan looking after RD and BD activities of Insilico Medicine in Asia markets.
He holds bachelor's degree in pharmacy and chemistry and master's degree in pharmacology both from National Taiwan University


See also: Company Insilico Medicine - Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Details last updated 24-Nov-2020

Jimmy Yen-Chu Lin News

Pharma company teams with AI to develop anti aging solutions

Longevity Technology - 15-Oct-2020

Taisho and Insilico collabs to identify novel targets for senolytic drugs